Mark Ledoux is a Neurology physician.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
5050 Poplar Ave Ste 511
Memphis, TN 381570500
Telephone
901-443-9170Provider last certified this registry record 26 Jan 2021.
Industry payments
20 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Teva Pharmaceuticals USA, Inc.Program year202549 payments$23,408openpaymentsdata.cms.gov ↗
- Amneal Pharmaceuticals LLCProgram year202520 payments$20,488openpaymentsdata.cms.gov ↗
- Merz Pharmaceuticals, LLCProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Musculoskeletal
64.2%Neuromuscular Blocker63.6%Incobotulinumtoxin a100%Part B, office-administered≥38 patientsgamma-Aminobutyric Acid-ergic Agonist0.5%Baclofen100%Part D≥27 patients+ 1 more class in this area
Nervous system
32.6%Aromatic Amino Acid Decarboxylation Inhibitor9.7%Carbidopa-Levodopa56%Rytary30%Carbidopa-Levodopa-Entacapone9%Carbidopa-Levodopa Er3%Carbidopa2%Part D<11 patientsMonoamine Oxidase Inhibitor3.2%Rasagiline Mesylate100%Part D≥139 patients+ 22 more classes in this area
Cardiovascular
0.9%Beta blocker0.4%Propranolol Hcl Er100%Part D≥18 patientsalpha-Adrenergic Agonist0.3%Midodrine Hcl100%Part D≥17 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
11 NIH research awards on record, funded 1995–2023 per NIH RePORTER. The latest:
- Pathobiology and Treatment of the UBTF E210K Neuroregression Syndrome
University of Memphis
FY2021$414,665R56NS123059
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Atte Meretoja
University of Helsinki
Bruce Miller, MD
University of California, San Francisco (UCSF)
Dennis Selkoe, MD
Brigham and Women's Hospital
Ettore Beghi
Mario Negri Institute for Pharmacological Research
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”